Rick A. Werner
Rick A. Werner is a member of the firm’s Executive Committee and co-chairs the firm's Capital Markets and Securities Practice. Rick represents issuers, investment banks and investors in a wide range of corporate transactions that include securities offerings, cross-border listings, venture capital financings and other forms of private equity investment, mergers and acquisitions, joint ventures and recapitalizations. Rick also advises clients on general corporate matters, securities compliance and reporting, and securities exchange compliance.
Rick's experience with public and private securities offerings includes initial and secondary offerings of equity and convertible securities, “at-the market” offerings, rights offerings, registered direct offerings and private investments in public equity (PIPEs). Rick also advises clients on alternative public offering transactions such as reverse mergers, de-SPACs, spin-offs and direct listings.
- Represented Gold Royalty Corp., a precious metals-focused royalty and streaming company, in its $90 million initial public offering and listing on the NYSE.
- Represented Pulmatrix, Inc., a clinical-stage biopharmaceutical company, in a reverse merger and financings that resulted in over $100 million of gross proceeds.
- Represented AYRO, Inc., a designer and manufacturer of electric, purpose-built delivery vehicles, in a reverse merger and financings that resulted in approximately $100 million of gross proceeds.
- Represented VBI Vaccines Inc., a biopharmaceutical company driven by immunology, in multiple financings for gross proceeds in excess of $200 million.
- Represented Eightco Holdings, Inc., a leading technology-driven e-commerce company, in its public spin-off on to Nasdaq and related financings that resulted in $42 million of gross proceeds.
- Represented PhaseRx, Inc., a biopharmaceutical company, in its $18.5 million initial public offering and Nasdaq listing.
- Represented Purple Biotech Ltd., a clinical-stage company developing therapies that seek to overcome tumor immune evasion and drug resistance, in its Nasdaq listing and multiple financings for gross proceeds of approximately $80 million.
- Represented RedHill Biopharma Ltd, a specialty biopharmaceutical company, in multiple financings for gross proceeds of approximately $220 million.
- Represented Kolibri Global Energy Inc., a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy, in its “MJDS” dual listing on Nasdaq.
- Represented NanoVibronix Inc., a medical device company, in its initial listing on Nasdaq and multiple financings for gross proceeds of approximately $20 million.
- Represented U.S. GoldMining Inc., an exploration and development company, in its $20 million initial public offering and Nasdaq listing.
- "8 Tips On Mining Disclosures For Foreign Issuers," co-author, Law360, November 6, 2023.
Education
B.A., Dartmouth College, 1997
J.D., University of California Los Angeles School of Law, 2000
Admissions
California
New York
A deal team from Haynes and Boone, LLP advised BiomX Inc. (NYSE: PHGE) in its merger with Adaptive Phage Therapeutics, Inc. (APT) and the concurrent $50 million private placement financing. The merger created an impactful phage therapy company with a robust pipeline, featuring two Phase 2 assets targeting chronic pulmonary infections in cystic fibrosis patients and diabetic foot osteomyelitis. The [...]
Haynes Boone Achieves Top-10 Rankings for Texas Capital Market Transactions in 2023
March 08, 2024
Haynes Boone Advises Firefly on Merger to Create NASDAQ-Listed Medical Technology Company
November 27, 2023
Werner, Digilova and Carroll in Law360: 8 Tips On Mining Disclosures For Foreign Issuers
November 06, 2023